

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13D**  
(Amendment No. 1) \*

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO  
§240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO  
240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**23ANDME HOLDING CO.**

---

(Name of Issuer)

---

Class A Common Stock, par value \$0.0001 per share  
(Title of Class of Securities)

---

90138Q 108  
(CUSIP Number)

---

Victoria A. Whyte  
GSK plc  
980 Great West Road  
Brentford, Middlesex TW8 9GS  
England  
Telephone: +44 (0)208 047 5000

---

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)

---

November 7, 2022  
(Date of Event which Requires Filing of this Statement)

---

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

---

---

---

1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

GSK plc

---

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(see instructions)

(a)

(b)

---

3. SEC USE ONLY

---

4. SOURCE OF FUNDS (see instructions)

OO

---

5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

---

6. CITIZENSHIP OR PLACE OF ORGANIZATION

England and Wales

---

7. SOLE VOTING POWER

39,660,487<sup>(1)</sup>

---

8. SHARED VOTING POWER

0

NUMBER OF SHARES  
BENEFICIALLY OWNED BY  
EACH REPORTING PERSON  
WITH

---

9. SOLE DISPOSITIVE POWER

39,660,487<sup>(1)</sup>

---

10. SHARED DISPOSITIVE POWER

0

---

11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

39,660,487<sup>(1)</sup>

---

12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

(see instructions)

---

13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

12.2%<sup>(2)</sup>

---

14. TYPE OF REPORTING PERSON (see instructions)

CO

---

Footnote:

(1) Represents shares of the Issuer's Class A common stock, par value \$0.0001 per share (the "Class A Common Stock") that may be obtained upon the conversion of shares of Class B Common Stock ("Class B Common Stock") held by the reporting persons. Class B Common Stock, which is not registered under the Securities Exchange Act of 1934, as amended, is convertible into shares of Class A Common Stock at the option of the holder on a share-for-share basis.

(2) The percentage reported herein is based upon (i) 286,738,037 shares of Class A Common Stock of 23andMe Holding Co. (the "Issuer") outstanding as of October 31, 2022, as reported in the Issuer's Form 10-Q furnished with the Securities and Exchange Commission (the "SEC") on November 7, 2022, and (ii) 39,660,487 shares of Class B Common Stock held directly by Glaxo Group Limited ("GGL"), an indirect wholly owned subsidiary of GSK plc ("GSK").

---

**Item 1. Security and Issuer.**

This Amendment No. 1 to Schedule 13D (this “Statement”) amends and supplements the statement on Schedule 13D originally filed on November 4, 2022 (the “Schedule 13D”) with respect to the Class A Common Stock of the Issuer, a Delaware incorporated company. GSK is filing this amendment to disclose its new percentage beneficial ownership in the Issuer, which has been decreased as a result of an increase in the outstanding Class A Common Stock of the Issuer. The Issuer’s principal executive offices are located at 349 Oyster Point Boulevard South San Francisco, California 94080.

**Item 5. Interest in Securities of the Issuer.**

The response set forth in Items 5 (a) of the Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:

- a. GSK beneficially owns 39,660,487 shares of Class B Common Stock, which represents 12.2% of the 286,738,037 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2022, as reported in the Issuer’s Form 10-Q on November 7, 2022 and the 39,660,487 shares of Class B Common Stock held by GGL.
-

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

Date: January 20, 2023

GSK plc

By: /s/ Victoria A. Whyte

Name: Victoria A. Whyte

Title: Authorized Signatory

---